
-
Connect Biopharma NasdaqGM:CNTB Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is headquartered in San Diego, California.
Location: 3580 CARMEL MOUNTAIN ROAD, San Diego, CA, 92130, United States | Website: https://www.connectbiopharm.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-39.72M
Cash
84.0M
Avg Qtr Burn
-8.245M
Short % of Float
0.53%
Insider Ownership
40.65%
Institutional Own.
43.97%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rademikibart (CBP-201) (Th2 cell modulator) Details Atopic dermatitis | Phase 3 Initiation | |
Rademikibart /CBP-201 (Th2 cell modulator) Details Acute Exacerbations in COPD | Phase 2 Data readout | |
Phase 2 Data readout | ||
Phase 2 Update | ||
CBP-174 (Peripherally restricted H3 receptor antagonist) Details Chronic pruritus | Phase 1 Update | |
Failed Discontinued | ||
Rademikibart (CBP-201) (Th2 cell modulator) Details Chronic rhinosinusitis, Chronic rhinosinusitis with nasal polyps | Failed Discontinued |